Niclosamide olamine
Based on 44 publication(s) in Google Scholar
Niclosamide (BAY2353) olamine is an orally active antihelminthic agent used in parasitic infection research. Niclosamide olamin is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells. Niclosamide olamin has biological activities against cancer, and inhibits DNA replication in Vero E6 cells.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 98.66%
- No. CAS: 1420-04-8
- Fòrmula: C15H15Cl2N3O5
- Peso molecular:388.20
-
Almacenamiento:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
HY-B0497
Niclosamide -
HY-B0497R
Niclosamide (Standard) -
HY-B0497CR
Niclosamide olamine (Standard) -
HY-B0497G
Niclosamide (GMP) -
HY-B0069
Fludarabine -
HY-17504
Rosuvastatin Calcium -
HY-13818
Stattic -
HY-B0167
Salicylic acid -
HY-B1436
Nifuroxazide -
HY-17504R
Rosuvastatin Calcium (Standard) -
HY-100753
STAT3-IN-1 -
HY-18980
Rottlerin
Publications Citing Use of MedChemExpress (MCE) Niclosamide olamine
More- Cell. 2025 Jun 26;188(13):3441-3458.e25. [Abstract]
- Cell Res. 2022 Jun;32(6):513-529. [Abstract]
- ACS Nano. 2025 Jul 15;19(27):25552-25565. [Abstract]
- ACS Nano. 2024 Aug 13;18(32):21268-21287. [Abstract]
- Adv Sci (Weinh). 2024 Aug;11(32):e2405332. [Abstract]
- Cell Death Dis. 2022 Feb 3;13(2):112. [Abstract]
- eGastroenterology. 2026 Mar 31;4(1):e100348. [Abstract]
- Oncogene. 2025 Sep 10. [Abstract]
- J Headache Pain. 2025 May 1;26(1):97. [Abstract]
- Int J Nanomedicine. 2025 Apr 5:20:4145-4163. [Abstract]
- Phytother Res. 2026 Jul;40(7):3936-3954. [Abstract]
- ACS Appl Mater Interfaces. 2024 Aug 28;16(34):44518-44527. [Abstract]
- Cell Syst. 2018 Apr 25;6(4):424-443.e7. [Abstract]
- Emerg Microbes Infect. 2022 Dec;11(1):483-497. [Abstract]
- Virulence. 2025 Oct 28:2580150. [Abstract]
- Biochem Pharmacol. 2019 Nov:169:113610. [Abstract]
- Oncogenesis. 2022 May 23;11(1):28. [Abstract]
- Nat Prod Bioprospect. 2025 Jun 13;15(1):39. [Abstract]
- Int J Mol Sci. 2023 Aug 11;24(16):12709. [Abstract]
- Int J Mol Sci. 2023 Feb 1;24(3):2749. [Abstract]
- Cell Signal. 2023 Aug:108:110717. [Abstract]
- iScience. 2025 Oct 27;28(11):113868. [Abstract]
- Antiviral Res. 2026 Jul:251:106421. [Abstract]
- Antiviral Res. 2022 Jan:197:105228. [Abstract]
- J Pharm Sci. 2026 Jul 21;115(9):104426. [Abstract]
- J Funct Foods. 2024 Oct.
- Viruses. 2022 Aug 6;14(8):1734. [Abstract]
- Viruses. 2021 Jun 3;13(6):1061. [Abstract]
- Viruses. 2021 Jun 28;13(7):1255. [Abstract]
- Int J Parasitol Drugs Drug Resist. 2025 Dec:29:100624. [Abstract]
- J Cancer. 2024 Jun 11;15(13):4406-4416. [Abstract]
- Exp Eye Res. 2023 Oct:235:109628. [Abstract]
- Leuk Lymphoma. 2021 Dec;62(14):3361-3372. [Abstract]
- Iran J Immunol. 2024 Sep 25;21(3). [Abstract]
- bioRxiv. 2026 Apr 9.
- Drug Repurposing. 2026 Jan 30.
- bioRxiv. 2025 Oct 27.
- bioRxiv. 2025 March 01.
- biorxiv. 2024 May 27.
- University of Gothenburg. 2023 Jun 27.
- Biomed Pharmacother. 2023 May:161:114422. [Abstract]
- L’UNIVERSITE GRENOBLE ALPES. 2021 Apr 13.
- Preprints. 2021, 2021040399.
- Patent. US20180263995A1.
Customer Validation & Images
-
WB
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
IF
Ver todos los productos específicos de isoformas Parasite
MoreVer todos los productos específicos de isoformas Antibiotic
More
Actividad biológica
Descripciòn
In Vitro
Niclosamide olamine (0.6 nM-46 µM) treatment inhibits adrenocortical carcinoma cellular proliferation in BD140A, SW-13, and NCI-H295R cells[3].Niclosamide olamine (0.05-5 μM, 24 h) treatment inhibits STAT3-mediated luciferase reporter activity in HeLa cells [4].Niclosamide olamine (10 μM) treatment inhibits virus replication in Vero E6 cells[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:BD140A, SW-13 and NCI-H295R cells
-
Concentration:0.6 nM-46 µM
-
Incubation Time:
-
Result:Inhibited cellular proliferation in adrenocortical carcinoma cell lines with the IC50 of 0.12 µM, 0.15 µM, and 0.53 µM in BD140A, SW-13, and NCI-H295R, respectively.
-
Cell Line:Hela cells
-
Concentration:0.05-5 μM
-
Incubation Time:24 hours
-
Result:Inhibited STAT3-mediated luciferase reporter activity with an IC50 of 0.25 μM.
-
Cell Line:Vero E6 cells
-
Concentration:10 μM
-
Incubation Time:2 days
-
Result:Inhibited the synthesis of viral antigens of SARS-CoV in Vero E6 cells.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nu+/Nu+ mice injected with NCI-H295R cells[3]
-
Dosage:100 mg/kg, 200 mg/kg
-
Administration:Oral gavage; 100 mg/kg, 200 mg/kg; once a week; 8 weeks
-
Result:Showed a 60%-80% inhibition in tumor growth, as compared to the control group.
Chemical Information
-
No. CAS 1420-04-8
-
Appearance Solid
-
Peso molecular 388.20
-
Fòrmula C15H15Cl2N3O5
-
Color Light yellow to yellow
-
SMILES
O=C(NC1=CC=C([N+]([O-])=O)C=C1Cl)C2=CC(Cl)=CC=C2O.NCCO
-
Synonyms
BAY2353 olamine
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (44)
-
Journal Impact Factor
-
Most Recent
-
Cell
2025 Jun 26;188(13):3441-3458.e25. PMID: 40280132 -
Cell Res
Derivation of totipotent-like stem cells with blastocyst-like structure forming potential. [Abstract]2022 Jun;32(6):513-529. PMID: 35508506 -
ACS Nano
An Asynchronous-Regulated Nanosheet Cascade Amplifies Sonodynamic-Triggered Self-Enhanced DNA Damage for Intensive Tumor Immunotherapy. [Abstract]2025 Jul 15;19(27):25552-25565. PMID: 40601833 -
ACS Nano
Biomineralization-Tuned Nanounits Reprogram the Signal Transducer and Activator of Transcription 3 Signaling for Ferroptosis-Immunotherapy in Cancer Stem Cells. [Abstract]2024 Aug 13;18(32):21268-21287. PMID: 39083438 -
Adv Sci (Weinh)
SNORA28 Promotes Proliferation and Radioresistance in Colorectal Cancer Cells through the STAT3 Pathway by Increasing H3K9 Acetylation in the LIFR Promoter. [Abstract]2024 Aug;11(32):e2405332. PMID: 38924373 -
Cell Death Dis
The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression. [Abstract]2022 Feb 3;13(2):112. PMID: 35115509 -
eGastroenterology
2026 Mar 31;4(1):e100348. PMID: 41948149 -
Oncogene
LEF1 confers resistance to DNA-damaging chemotherapies through upregulation of PARP1 and NUMA1 in ovarian cancer. [Abstract]2025 Sep 10. PMID: 40931049 -
J Headache Pain
Inhibition of S100A4 decreases neurotoxic astrocyte reactivity and attenuates neuropathic pain via the TLR4/NF-κB pathway in a rat model of spinal nerve ligation. [Abstract]2025 May 1;26(1):97. PMID: 40312684 -
Int J Nanomedicine
Electromechanical Regulation Underlying Protein Nanoparticle-Induced Osmotic Pressure in Neurotoxic Edema. [Abstract]2025 Apr 5:20:4145-4163. PMID: 40207308 -
Phytother Res
Activation of MTCH2 by Momordin Ic Prevents Colitis and Colitis-Associated Colorectal Cancer Through Rescuing the Mitochondrial Dysfunction of Macrophage. [Abstract]2026 Jul;40(7):3936-3954. PMID: 42007543 -
ACS Appl Mater Interfaces
Albumin-Based Microneedles for Spatiotemporal Delivery of Temozolomide and Niclosamide to Resistant Glioblastoma. [Abstract]2024 Aug 28;16(34):44518-44527. PMID: 39145481 -
Cell Syst
A Library of Phosphoproteomic and Chromatin Signatures for Characterizing Cellular Responses to Drug Perturbations. [Abstract]2018 Apr 25;6(4):424-443.e7. PMID: 29655704 -
Emerg Microbes Infect
Obatoclax inhibits SARS-CoV-2 entry by altered endosomal acidification and impaired cathepsin and furin activity in vitro. [Abstract]2022 Dec;11(1):483-497. PMID: 34989664 -
Virulence
Newcastle disease virus acquires phosphatidylserine through the budding process to enhance infectivity. [Abstract]2025 Oct 28:2580150. PMID: 41147668 -
Biochem Pharmacol
Repurposing of the anti-helminthic drug niclosamide to treat melanoma and pulmonary metastasis via the STAT3 signaling pathway. [Abstract]2019 Nov:169:113610. PMID: 31465777 -
Oncogenesis
GSK3β palmitoylation mediated by ZDHHC4 promotes tumorigenicity of glioblastoma stem cells in temozolomide-resistant glioblastoma through the EZH2-STAT3 axis. [Abstract]2022 May 23;11(1):28. PMID: 35606353 -
Nat Prod Bioprospect
Exploring anti-SARS-CoV-2 natural products: dual-viral target inhibition by delphinidin and the anti-coronaviral efficacy of deapio platycodin D. [Abstract]2025 Jun 13;15(1):39. PMID: 40512442 -
Int J Mol Sci
S100A4 Promotes BCG-Induced Pyroptosis of Macrophages by Activating the NF-κB/NLRP3 Inflammasome Signaling Pathway. [Abstract]2023 Aug 11;24(16):12709. PMID: 37628889 -
Int J Mol Sci
The Activation of Reticulophagy by ER Stress through the ATF4-MAP1LC3A-CCPG1 Pathway in Ovarian Granulosa Cells Is Linked to Apoptosis and Necroptosis. [Abstract]2023 Feb 1;24(3):2749. PMID: 36769070 -
Cell Signal
STAT1/3 signaling suppresses axon degeneration and neuronal cell death through regulation of NAD+-biosynthetic and consuming enzymes. [Abstract]2023 Aug:108:110717. PMID: 37187216 -
iScience
Niclosamide suppresses gastric cancer progression through YTHDF2 inhibition-affected lactate metabolic reprogramming. [Abstract]2025 Oct 27;28(11):113868. PMID: 41323282 -
Antiviral Res
Niclosamide inhibits the replication of highly pathogenic avian influenza A (H5Nx) viruses and antiviral-resistant mutants. [Abstract]2026 Jul:251:106421. PMID: 42070632 -
Antiviral Res
2022 Jan:197:105228. PMID: 34929248 -
J Pharm Sci
Niclosamide ethanolamine induces malignant phyllodes tumor cell death via mTOR-TFEB axis-mediated lysosomal biogenesis and functional uncoupling. [Abstract]2026 Jul 21;115(9):104426. PMID: 42480904 -
-
Viruses
2022 Aug 6;14(8):1734. PMID: 36016355 -
Viruses
M Segment-Based Minigenome System of Severe Fever with Thrombocytopenia Syndrome Virus as a Tool for Antiviral Drug Screening. [Abstract]2021 Jun 3;13(6):1061. PMID: 34205062 -
Viruses
Screening and Identification of Lujo Virus Inhibitors Using a Recombinant Reporter Virus Platform. [Abstract]2021 Jun 28;13(7):1255. PMID: 34203149 -
Int J Parasitol Drugs Drug Resist
Evaluation of the inhibitory effects of emodin on Neospora caninum invasion and proliferation in vitro. [Abstract]2025 Dec:29:100624. PMID: 41187614 -
J Cancer
Treatment of HNSC and pulmonary metastasis using the anti-helminthic drug niclosamide to modulate Stat3 signaling activity. [Abstract]2024 Jun 11;15(13):4406-4416. PMID: 38947381 -
Exp Eye Res
Niclosamide inhibits TGF-β1-induced fibrosis of human Tenon's fibroblasts by regulating the MAPK-ERK1/2 pathway. [Abstract]2023 Oct:235:109628. PMID: 37619828 -
Leuk Lymphoma
2021 Dec;62(14):3361-3372. PMID: 34355652 -
Iran J Immunol
2024 Sep 25;21(3). PMID: 39319693 -
-
-
-
-
-
-
Biomed Pharmacother
2023 May:161:114422. PMID: 36841028
Niclosamide olamine purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 May:161:114422. [Abstract]
Niclosamide (NIC; 5 μM; 24 h) significantly reduces cyclin D1 and vimentin protein expression in human endometrial cancer cells.
Niclosamide olamine purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 May:161:114422. [Abstract]
Niclosamide (NIC; 0-8 μM; 24, 48, 72 h) significantly inhibits the metabolic viability of AN3CA, Hec1B, and Ishikawa cells both in a dose-dependent and a time-dependent manner, with the half maximal inhibitory concentration of < 1 μM at 72 h.
Niclosamide olamine purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 May:161:114422. [Abstract]
Niclosamide (NIC) significantly suppresses the colony formation ability, and reduces the numbers, as well as diameters, of colonies formed in AN3CA, Hec1B, and Ishikawa cells.
Niclosamide olamine purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 May:161:114422. [Abstract]
Niclosamide (NIC; 1 μM) reduces number of cells that invaded across the trans-well chamber in Hec1B and Ishikawa endometrial cancer cell lines, suggesting NIC-mediated inhibition of invasive property of endometrial cancer cells.
-
-
-
Solvente y solubilidad
In Vitro:
DMSO : 125 mg/mL (322.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Pureza y Documentación
-
Ficha de datos (280 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. P Andrews, et al. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19(2):245-95. [Content Brief]
[2]. Wei Chen, et al. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018 Jan;41:89-96. [Content Brief]
[3]. Kei Satoh, et al. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clin Cancer Res. 2016 Jul 15;22(14):3458-66. [Content Brief]
[4]. Xiaomei Ren, et al. Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett. 2010 Sep 7;1(9):454-9. [Content Brief]
[5]. Chang-Jer Wu, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.5760 mL | 12.8800 mL | 25.7599 mL | 64.3998 mL |
| 5 mM | 0.5152 mL | 2.5760 mL | 5.1520 mL | 12.8800 mL | |
| 10 mM | 0.2576 mL | 1.2880 mL | 2.5760 mL | 6.4400 mL | |
| 15 mM | 0.1717 mL | 0.8587 mL | 1.7173 mL | 4.2933 mL | |
| 20 mM | 0.1288 mL | 0.6440 mL | 1.2880 mL | 3.2200 mL | |
| 25 mM | 0.1030 mL | 0.5152 mL | 1.0304 mL | 2.5760 mL | |
| 30 mM | 0.0859 mL | 0.4293 mL | 0.8587 mL | 2.1467 mL | |
| 40 mM | 0.0644 mL | 0.3220 mL | 0.6440 mL | 1.6100 mL | |
| 50 mM | 0.0515 mL | 0.2576 mL | 0.5152 mL | 1.2880 mL | |
| 60 mM | 0.0429 mL | 0.2147 mL | 0.4293 mL | 1.0733 mL | |
| 80 mM | 0.0322 mL | 0.1610 mL | 0.3220 mL | 0.8050 mL | |
| 100 mM | 0.0258 mL | 0.1288 mL | 0.2576 mL | 0.6440 mL |
Niclosamide olamine Related Classifications
HY-B0497C Related Classifications
Powered by Bioz